India, which is one of the manufacturing bases for the new coronavirus vaccine, has announced that it will resume the overseas supply of vaccines that had been suspended due to the explosive spread of the infection in the country by the end of the year. It is expected that supply will increase to developing countries where there is a shortage of vaccines.
India is one of the manufacturing bases for the new coronavirus vaccine, and the Indian government has provided or exported the domestically produced AstraZeneca vaccine to other countries free of charge, but due to the explosive spread of the infection, it is domestic. Demand for vaccines has increased, and supply to foreign countries has been suspended since late April.
The number of people infected per day in India reached more than 400,000 in early May, but now it has decreased to around 30,000, and the Minister of Health and Family Welfare Mandavia issued a statement on the 20th and went abroad. The company has announced that it will resume the supply of vaccines by the end of the year.
Vaccine production is also accelerating, and it is expected that 300 million vaccines will be produced each month in the future.
Through the "COVAX Facility", a framework led by the WHO = World Health Organization, India was planning to supply 70% of the vaccine that was planned to be distributed to the world in the first half, so it is still in the process of being stopped. It was one of the factors behind the delay in securing vaccines, especially in the country.
Although the specific timing and quantity of the resumption of supply have not been clarified, the Indian government has stated that it will fulfill its responsibility to the COVAX facility, and it is expected that the supply of vaccines to developing countries will increase in the future.